Refining endpoints for stroke recovery trials

Affiliations

¹ Department of Neurology, University Hospital Essen, University of Duisburg-Essen, D-45122 Essen, Germany. Electronic address: dirk.hermann@uk-essen.de.
² Department of Neurology, University Hospital Berne, Berne, Switzerland.
³ Institut de Recherches Internationales Servier (IRIS), Suresnes, France.
⁴ Department of Neurology, Lariboisière Hospital, Paris Diderot University and INSERM U1141, Paris, France.

Comment

Dirk M Hermann et al. Lancet Neurol. 2020 May.

. 2020 May;19(5):381-382.

doi: 10.1016/S1474-4422(20)30101-0.

¹ Department of Neurology, University Hospital Essen, University of Duisburg-Essen, D-45122 Essen, Germany. Electronic address: dirk.hermann@uk-essen.de.
² Department of Neurology, University Hospital Berne, Berne, Switzerland.
³ Institut de Recherches Internationales Servier (IRIS), Suresnes, France.
⁴ Department of Neurology, Lariboisière Hospital, Paris Diderot University and INSERM U1141, Paris, France.

No abstract available

Comment on

Issues important to the design of stroke recovery trials.
Cramer SC. Cramer SC. Lancet Neurol. 2020 Mar;19(3):197-198. doi: 10.1016/S1474-4422(20)30030-2. Lancet Neurol. 2020. PMID: 32085829 No abstract available.
Safety and efficacy of GABA_A α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial.
Chabriat H, Bassetti CL, Marx U, Audoli-Inthavong ML, Sors A, Lambert E, Wattez M, Hermann DM; RESTORE BRAIN study investigators. Chabriat H, et al. Lancet Neurol. 2020 Mar;19(3):226-233. doi: 10.1016/S1474-4422(20)30004-1. Lancet Neurol. 2020. PMID: 32085836 Clinical Trial.